Feature | May 11, 2010| Dave Fornell

Fluid Status Monitoring May Offer Early Heart Failure Warning

Monitoring congestive heart failure patients for any worsening in their condition is based mainly on patient compliance to accurately weigh themselves every day and report any unusual symptoms. A technology introduced on Medtronic implantable electrophysiology devices may help to more closely monitor patients and alert physicians to any fluid buildup in the lungs before the patient detects any changes.

OptiVol fluid status monitoring is found on Medtronic’s latest wireless defibrillators, including the Consulta and Concerto cardiac resynchronization therapy defibrillators (CRT-Ds), and the Secura and Virtuoso implantable cardioverter-defibrillators (ICDs).

The device was tested in the Fluid Accumulation Status Trial (FAST) FDA trial from 2006 to 2008. The principal investigator was William T. Abraham, M.D., FACC, professor of internal medicine and director of the division of cardiovascular medicine at the Ohio State University Medical Center (OSU), Columbus. He said it’s a simple principle, using ICDs, pacemakers and CRTs already implanted in the body to help monitor patients. The device passes a small current through the tip of a lead to measure the resistance to the flow of electrons through the chest. As the lungs fill with water, the resistance falls. This sends an alert via Medtronic’s Carelink remote device monitoring system, or is detected with a wand during patient follow-up.

The study compared the device index to the gold standard of measuring weight. “The OptiVol performed much better than daily weight monitoring,” Dr. Abraham said. The sensitivity was 22 percent with weight measurement, compared to 76 percent with OptiVol. “We probably should not be as dependant on daily weight, but it is a standard of care because we haven’t had anything better.”

However, OptiVol is only an indicator and should not be used as a sole diagnostic tool. “It can’t be used in isolation, you can’t base your decision solely on the device data,” Dr. Abraham said. “It’s another piece of the monitoring data that goes into the clinical decision making.”

“We have a very large heart failure management program at OSU, with about 3,000 to 4,000 patients, many using the OptiVol technology,” he said.

No study has been conducted to evaluate if the feature lowers hospitalizations. However, Dr. Abraham said his experience with patients at OSU has shown a reduction in hospitalizations in some patients.

Related Content

AtriCure's AtriClip System Surpasses 100,000 Units Sold Worldwide
News | Left Atrial Appendage (LAA) Occluders| April 25, 2017
AtriCure Inc. announced it has sold more than 100,000 AtriClip Left Atrial Appendage Exclusion System devices worldwide...
Clinical Study Validates Efficiencies of Stereotaxis Niobe ES System Over Niobe II System
News | Robotic Systems| April 24, 2017
A recent study conducted at Centre Hospitalier Universitaire (CHU) of Saint-Étienne, France validated the advantages of...
Digital Health Company Murj Announces $4.5 Million in Financing
News | Implantable Cardiac Monitor (ICM)| April 19, 2017
Murj Inc., a digital health company that helps manage implantable cardiac device data, announced more than $4.5 million...
NICE Recommends Boston Scientific CRT-Ds With EnduraLife Battery Technology for Heart Failure Treatment
News | Cardiac Resynchronization Therapy Devices (CRT)| April 14, 2017
The National Institute for Health and Care Excellence (NICE) recently issued medical technology guidance recommending...
The Unify ICD is one of the SJM devices in an FDA warning letter
Feature | Implantable Cardioverter Defibrillators (ICD)| April 14, 2017 | Dave Fornell
April 14, 2017 — The U.S. Food and Drug Administration (FDA) sent a warning letter to Abbott/St.
An electrophysiology EP ablation procedure to treat a heart arrhythmia
Feature | HRS| April 14, 2017
April 14, 2017 — The Heart Rhythm Society (HRS) has announced its late-breaking clinical trials at its annual meeting
Vascular Dynamics Completes $10.4 Million Financing for MobiusHD System
News | Hypertension| April 13, 2017
Vascular Dynamics Inc. (VDI) a privately held medical device company developing novel solutions for the treatment of...
Biotronik Launches New ICD Lead With Helical Design in Europe
News | Leads Implantable Devices| April 12, 2017
Biotronik announced the European launch of a new lead for tachycardia therapy that features a helical design for...
The Arctic Front Advance Cardiac CryoAblation Catheter treats atrial fibrillation with pulmonary vein isolation
News | Atrial Fibrillation| April 11, 2017
April 10, 2017 — Medtronic recently announced the first enrollments in the STOP Persistent AF clinical trial.
Sponsored Content | Videos | EP Lab| April 10, 2017
A discussion with Heart Rhythm Society (HRS) President Michael Gold, M.D., Ph.D., director of cardiology and associat
Overlay Init